Latest End point of clinical trials Stories
Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival LAWRENCEVILLE, N.J., July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ:
SUNNYVALE, Calif., July 25, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo.
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival.
SAN DIEGO, June 3, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy.
Pre-specified MGMT and HLA Subgroup Analyses Show Potentially Clinically Meaningful Survival Advantages for ICT-107 Treated Patients LOS ANGELES, June 1, 2014 /PRNewswire/ -- ImmunoCellular
Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/
Latest Data Sweep from Large Subgroup of Patients Shows a Strong 50% Improvement in Overall Survival for ThermoDox® LAWRENCEVILLE, N.J., April 24, 2014 /PRNewswire/ -- Celsion Corporation
Professor Riccardo Lencioni is giving an honorary lecture on April 24, 2014 which will highlight the latest findings and lessons learned from the HEAT Study and the design of the Phase III OPTIMA Study LAWRENCEVILLE,
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).